We use cookies to make sure our website better meets your expectations.
You can adjust your web browser's settings to stop accepting cookies. For further information, read our cookie policy.
SEARCH
IN Warsaw
Exchange Rates
Warsaw Stock Exchange - Indices
The Warsaw Voice » Business » March 12, 2018
You have to be logged in to use the ReadSpeaker utility and listen to a text. It's free-of-charge. Just log in to the site or register if you are not registered user yet.
OncoArendi biotech to offer up to 2 million new shares
March 12, 2018   
Article's tools:
Print

Biotechnological firm OncoArendi Therapeutics, specializing in oncological drugs, plans to offer from 500 k to 2 mln new shares under an IPO slated for the turn of March and April, the company said in a press statement.
"The company's intention is to offer ca. 90% of shares to institutional investors and ca. 10% of shares to individual investors," the statement read.
The company's significant shareholders agreed to a lock-up of 360 days.

Final timing of the IPO will depend on securing approval of the IPO prospectus from financial market watchdog KNF, as well as on the situation on the market, the company said.
Brokerage Trigon DM acts as the IPO manager.
Prominent WSE investor Michal Solowow is among OncoArendi's investors.
© The Warsaw Voice 2010-2018
E-mail Marketing Powered by SARE